L. Fabbri (Modena, Italy), K. F. Rabe (Leiden, The Netherlands)
Treatment of co-morbid allergic asthma and perennial allergic rhinitis with the anti-IgE agent omalizumab
A. M. Vignola, J. Bousquet, J. Maspero, H. Fox, S. Hedgecock, M. Blogg (Palermo, Italy; Montpellier, France; Buenos Aires, Argentina; Horsham, United Kingdom)
|  |
Efficacy of omalizumab in patients with moderate-to-severe allergic asthma that is poorly controlled on GINA (1998) treatment step 3 or 4
J. Bousquet, R. Niven, G. Ayre, H. Fox, M. Blogg (Montpellier, France; Manchester, Horsham, United Kingdom)
| |
Anti-IgE therapy with omalizumab decreases exacerbations in patients with poorly controlled moderate-to-severe allergic asthma
F. Chung, G. Kunkel, S. Ramos, G. Ayre, H. Fox, M. Blogg (London, Horsham, United Kingdom; Berlin, Germany; Oviedo, Spain)
| |
Effect of treatment with anti-IgE antibody on airway inflammation in mild asthma
R. Djukanovic, S. J. Wilson, M. Kraft, N. Jarjour, M. Steel, F. K. Chung, W. Bao, A. Fowler Taylor, J. Mathews, W. W. Busse, S. T. Holgate, J. V. Fahy (Southampton, United Kingdom)
| |
The novel selective PDE4 inhibitor roflumilast: early onset of efficacy in asthma
M. Aubier, G. B. Nagy, R. Sauer, C. Schmid-Wirlitsch, A. Albrecht, D. Bredenbroker (Paris, France; Budapest, Hungary; Ulm, Konstanz, Germany)
| |
Roflumilast, a selective phosphodiesterase 4 inhibitor, shows efficacy and safety in the long-term treatment of asthma
E. D. Bateman, J. L. Izquierdo, N. Vetter, C. Schmid-Wirlitsch, D. Bredenbroeker (Cape Town, South Africa; Guadalaljara, Spain; Vienna, Austria; Konstanz, Germany)
| |
Effect of an inhaled adenosine A2A agonist on the allergen induced late asthmatic response
B. Luijk, M. van den Berge, H. A. Kerstjens, D. D. Postma, J. W. J. Lammers (The Netherlands)
| |